drugset / Trial / NCT06353646
XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a single-center, open label, single-arm, investigator-initiated study to evaluate the efficacy and safety of XH001 (neoantigen cancer vaccine) sequential combination with immunocheckpoint inhibitor and chemotherapy in pancreatic cancer patients following surgical resection.
Timeline
- Start
- 2024-03-12
- Primary completion
- 2026-06
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | — | — |
| Subject | Sintilimab | Monoclonal antibody | — | — |
| Subject | XH001 | Vaccine | — | — |
| Background | Capecitabine | Small molecule | — | — |
| Background | Gemcitabine | Small molecule | — | — |